Optimizing diagnosis and treatment for severe pneumonia using multi-omics data
Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration
Capital Medical University · NCT06288074
This study is trying to find better ways to diagnose and treat severe pneumonia by looking at different biological data to help patients get the right medication faster.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Capital Medical University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06288074 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with severe community-acquired pneumonia caused by various pathogens to explore the molecular mechanisms and identify prognostic biomarkers. By integrating multi-omics data, the research aims to evaluate the effectiveness of initial empirical medication and develop a precise treatment strategy. The findings could lead to rapid and accurate clinical diagnosis and efficacy evaluation for severe pneumonia, ultimately improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a clinical diagnosis of community-acquired pneumonia.
Not a fit: Patients who are pregnant, lactating, or have certain immunosuppressive or blood system diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective and personalized treatment approach for patients suffering from severe pneumonia.
How similar studies have performed: While the integration of multi-omics data in pneumonia treatment is a novel approach, similar studies in other conditions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age\> 18 years old Clinical diagnosis of community-acquired pneumonia Exclusion Criteria: Pregnancy, perinatal and lactating women Combined immunosuppressive diseases: such as HIV, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy Combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation
Where this trial is running
Beijing, Beijing
- Beijing Institute of Respiratory Medicine — Beijing, Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Zhaohui Tong, Dr
- Email: 13910930309@163.com
- Phone: +86 139 1093 0309
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Severe Community-acquired Pneumonia